Actinium Pharmaceuticals (NYSE: ATNM) is a clinical-stage biopharmaceutical company engaged in developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company’s radio-immunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. The company’s product pipeline includes Iomab-B CD45 to treat myeloablation prior to Bone Marrow Transplant (BMT), patients over age 55 with relapsed or refractory AML and induction and conditioning agent prior to a BMT1; Actimab-A (f.d.) CD33 to treat AML and newly diagnosed patients with AML over age 60; Actimab-M CD33 to treat multiple myeloma and relapsed or refractory patients age 18 and above; Actimab-MDS CD33 to treat myelodysplastic syndrome (MDS) and myeloablation prior to BMT for high-risk MDS patients with a p53 genetic mutation; Actinium-225 conjugated to daratumumab, a CD38 targeting agent to treat multiple myeloma; Actimab-C to treat colon cancer; Actimab-P to treat prostate cancer; and Actimab-Br to treat brain cancer. For more information, visit the company’s website at www.actiniumpharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
